Medical Equipment company Tarsons Products announced Q1FY26 results Revenue: Rs 91.4 crore compared to Rs 84.8 crore during Q1FY25, change 8%. EBITDA: Rs 24.7 crore compared to Rs 18.8 crore during Q1FY25, change 32%. EBITDA Margin: 27.0% for Q1FY26. PAT: Rs 1.8 crore compared to Rs 4.0 crore during Q1FY25, change -56%. PAT Margin: 2.0% for Q1FY26. Aryan Sehgal, Promoter & Whole Time Director of Tarsons, said: We are pleased to report a YoY revenue growth of 10% and an EBITDA growth of 31% on a standalone basis. Domestic revenues in Q1FY26 saw a healthy uptick of approximately 12%, reflecting early signs of recovery in the life sciences industry and our ability to capture increased market share. While these signs of revival remain somewhat volatile, the current order pipeline and ongoing customer inquiries give us confidence in sustaining growth through FY26 and beyond. Profit After Tax for the current period was impacted due to accelerated depreciation following the capitalisation of our new facility. However, as revenue contribution from this plant ramps up, we expect to benefit from strong operating leverage, leading to improved overall EBITDA and PAT in the coming periods. Our Cash PAT in the interim grew by 38% on a standalone basis & by 44% on consolidated levels. With the addition of new product categories enabled by the commissioning of our new facility at Panchla, we will be positioned to address a broader market, supporting our growth ambitions and helping us outperform industry trends. Backed by the strong brand equity of Tarsons and our extensive pan-India distribution network, we are optimistic about achieving similar market share in these new categories as we currently command for our existing product portfolio. We remain committed to the industry's long-term growth prospects and have continued to invest through the down cycle to strengthen our capacities and capabilities, positioning ourselves for sustainable growth over the next 3–5 years. Backed by the strong brand equity of Tarsons and our consistent track record of delivering high-quality products, we are confident in our ability to capture greater market share in our existing product lines while accelerating the adoption of our newly introduced offerings.” Result PDF